BioWorld

Sep. 23, 2003

View Archived Issues

BioMarin Stops Development Of Neutralase In CABG Surgery

Officials at BioMarin Inc. believe themselves to be fortunate in determining fairly early that their lead product, Neutralase, probably won't make it to market. (BioWorld Today) Read More

Pain Therapeutics Raises $49.7M In Follow-On; Neose Getting $23M

Read More

Controversy Smolders As To U.S. Regions Of Lyme Disease, Borrelia burgdorferi, Despite M.D. Practices

Read More

First-Round Financing Of $12.5M Puts Ambrx On Development Path

Read More

Genzyme Invests $37.7M In CAT As Companies Restructure Pact

Read More

Other News To Note

Read More